Patrys raises $3.4m to fund product trials
Monday, 05 December, 2011
Melbourne-based Patrys (ASX:PAB) has raised $3.4 million in new capital to fund the development of its prospective antibody-based cancer treatments.
Patrys has announced the allocation of 113.5 million new shares at $0.03 per share through an oversubscribed placement.
The funds will be used to fund trials of its products, including the final stages of a phase I trial for use of its PAT-SM6 product as a melanoma treatment.
The same product also the subject of a phase I/IIa clinical trial as a treatment for multiple myeloma – a type of bone marrow cancer.
Patrys also plans to use the windfall to help fund preclinical development of another antibody which has shown promise as a potential treatment for colon, lung, breast, ovarian and pancreatic cancers.
The company is also in the process of commercialising its most advanced product, gastric cancer treatment, PAT-SC1, and will use the placement funds to support business development and licensing activities.
Though Patrys' headquarters are in Melbourne, its main R&D centre is in Würzburg, Germany. The company was listed on the ASX in 2007.
Patrys (ASX:PAB) shares rose 8.11% in Monday's trading to $0.040. The stock price has generally been trending down since July.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
